Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore Cardiovascular Risk Reduction Benefits of Eicosapentaenoic Acid ("EPA") for Patients TORONTO, Nov. 7, 2022 /CNW/ - HLS...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 Fiscal 2022 financial results on Thursday, November 10, 2022. The Company will hold a conference...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces updates to its credit agreement and...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in Renmark...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive...